HTR3D Antibody

What is HTR3D and why is it important in neuroscience research?

HTR3D (5-hydroxytryptamine receptor 3D) is a subunit of the serotonin type 3 receptor family that forms cation-selective channel complexes when activated by serotonin. Unlike many G-protein coupled receptors, 5-HT3 receptors function as ligand-gated ion channels, causing fast, depolarizing responses in neurons . HTR3D is important in neuroscience research because:

• It contributes to serotonergic signaling involved in learning, cognition, and emotion

• It has been implicated in psychiatric disorders including bipolar affective disorder

• It typically requires assembly with HTR3A to form functional receptors

• It is primarily expressed in the central nervous system, particularly in regions relevant to psychiatric disorders

When conducting experiments targeting HTR3D, researchers should consider its cellular localization, as it is primarily a multi-pass membrane protein that is "presumably retained within the endoplasmic reticulum unless complexed with HTR3A" .

What applications are HTR3D antibodies suitable for in research settings?

Based on available research tools, HTR3D antibodies are validated for several key applications:

When selecting an antibody for a specific application, researchers should review validation data for the specific antibody product, as reactivity and performance can vary significantly between different antibodies targeting the same protein .

What are the important technical specifications to consider when selecting an HTR3D antibody?

When selecting an HTR3D antibody for research, consider these key specifications:

• Host species and isotype: Available in rabbit polyclonal (IgG) and mouse monoclonal formats

• Epitope region: Target regions vary between products (e.g., amino acids 10-90, 378-396)

• Reactivity: Most are human-specific, though some offer cross-reactivity with mouse or rat

• Formulation: Typically provided in PBS with glycerol, BSA, and sodium azide as preservatives

• Purification method: Most are affinity-purified using epitope-specific immunogens

• Storage requirements: Generally stable at -20°C for up to 1 year, avoid freeze-thaw cycles

For optimal results, researchers should select antibodies with validation data relevant to their experimental design and target tissue/cell type. The specificity should be confirmed through appropriate controls, particularly when working with related serotonin receptor family members .

How can I validate the specificity of an HTR3D antibody in my experimental system?

Validation of HTR3D antibody specificity requires multiple complementary approaches:

• Genetic controls:

  • Use CRISPR/Cas9 knockout systems targeting HTR3D (available as plasmids)

  • Compare staining patterns in cells with HTR3D overexpression versus control cells

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide before application

  • Loss of signal confirms epitope-specific binding

• Cross-validation with multiple antibodies:

  • Use antibodies targeting different epitopes of HTR3D

  • Concordant results strengthen confidence in specificity

• Molecular weight verification:

  • HTR3D has a calculated molecular weight of approximately 55 kDa

  • Verify band position in Western blot matches theoretical weight

• Negative controls:

  • Test in tissues known not to express HTR3D (e.g., cerebellum)

  • Include isotype control antibodies to rule out non-specific binding

For definitive validation, combining genetic approaches with biochemical verification provides the strongest evidence of antibody specificity .

What are the methodological considerations for detecting HTR3D in native brain tissues?

Detecting HTR3D in native brain tissues presents several challenges requiring specialized techniques:

• Tissue preparation:

  • Fresh frozen tissues generally yield better results than formalin-fixed

  • For IHC/IF, antigen retrieval is critical (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Perfusion fixation improves signal-to-noise ratio in brain sections

• Expression patterns:

  • HTR3D is expressed in specific brain regions including the hippocampus, cortex, and amygdala

  • Signal may be weak due to naturally low expression levels

  • Consider using signal amplification methods (e.g., TSA)

• Co-staining strategies:

  • Co-stain with HTR3A to identify functional receptor complexes

  • Use neuronal markers to distinguish neuronal from non-neuronal expression

• Species considerations:

  • Expression patterns differ between rodents and humans

  • Verify antibody cross-reactivity if working with animal models

• Controls:

  • Include positive control tissue with known HTR3D expression

  • Use 6E10 antibody as a comparative marker in AD studies

Research has shown that HTR3A interneurons are abundant in the hippocampus and cortex relative to other forebrain regions in both rodents and humans, primarily located in the stratum radium and lacunosum molecular layer of hippocampus and molecular layer of dentate gyrus .

How should HTR3D antibodies be used to investigate serotonin receptor heteromeric complexes?

Investigating HTR3D in heteromeric receptor complexes requires specialized approaches:

• Co-immunoprecipitation (Co-IP):

  • Use HTR3D antibodies to pull down protein complexes

  • Probe for HTR3A or other potential interaction partners

  • Use mild detergents (e.g., CHAPS, digitonin) to preserve membrane protein interactions

• Proximity ligation assays (PLA):

  • Detect protein-protein interactions with spatial resolution

  • Requires antibodies raised in different species against HTR3D and potential partners

• FRET/BRET approaches:

  • For live cell imaging of receptor associations

  • Requires genetic fusion of fluorescent/luminescent tags

• Sequential immunoprecipitation:

  • First IP with anti-HTR3D

  • Second IP with anti-HTR3A to isolate heteromeric complexes

Remember that HTR3D is "presumably retained within the endoplasmic reticulum unless complexed with HTR3A" , which means detection of surface expression likely indicates heteromeric complex formation. This characteristic can be exploited as an indirect measure of complex formation in cell systems.

How can HTR3D antibodies be applied in studies of psychiatric disorders?

HTR3D antibodies provide valuable research tools for investigating psychiatric conditions:

• Genetic variant correlation:

  • The variant HTR3B p.Y129S (c.386A>C, rs1176744) has been associated with bipolar affective disorder with a pooled odds ratio of 0.881 (P=0.009)

  • Antibodies can help determine if genetic variants alter protein expression levels

• Post-mortem tissue analysis:

  • Compare HTR3D expression in patient vs. control brain samples

  • Assess receptor distribution in affected brain regions

  • Study co-localization with other disease markers

• Functional correlations:

  • HTR3 receptor function appears impaired in BPAD

  • Antibodies can help determine if expression changes correlate with functional alterations

• Sex-specific differences:

  • Research shows sex-specific associations of HTR3 variants with psychiatric phenotypes

  • "CMH analyses showed a clear sex-specific association" with the p.Y129S variant in males (P=0.0002) but not females

  • Use antibodies to investigate sex-specific expression patterns

• Animal models:

  • HTR3A knockout mice show reduced anxiety-like behavior

  • "Regulation of depression- and anxiety-related behaviors by the 5-HT3A subunit differs between males and females"

  • Antibodies can verify knockdown efficiency and compensatory changes

These approaches help connect genetic findings to molecular mechanisms in psychiatric disorders, bridging the gap between genomic association studies and functional understanding.

What methodological approaches can resolve challenges in detecting low-abundance HTR3D in native tissues?

Detecting low-abundance HTR3D in native tissues requires enhanced techniques:

• Signal amplification methods:

  • Tyramide signal amplification (TSA) can increase sensitivity 10-100 fold

  • HRP-conjugated secondary antibodies with amplification substrates

  • Consider using biotinylated secondary antibodies with streptavidin-HRP

• Tissue enrichment strategies:

  • Microdissection of relevant brain regions

  • Cell sorting to isolate specific neuronal populations

  • Subcellular fractionation to concentrate membrane proteins

• Optimized protein extraction:

  • Use specialized membrane protein extraction buffers

  • Incorporate detergents suitable for transmembrane proteins (e.g., DDM, CHAPS)

  • Consider native extraction conditions to preserve complex integrity

• Enhanced detection systems:

  • Ultrasensitive Western blot substrates

  • Fluorescence-based detection with high-sensitivity cameras

  • Quantum dot-conjugated secondary antibodies for enhanced signal

• Modified IHC/IF protocols:

  • Extended primary antibody incubation (overnight at 4°C)

  • Multiple-round antibody application

  • Signal enhancement using nanoboosters or other amplifiers

These approaches must be carefully validated with appropriate controls to ensure that enhanced signals remain specific to HTR3D rather than introducing artifacts or background .

How do antibody-based approaches complement genetic studies of HTR3D in psychiatric disorders?

Antibody-based approaches provide crucial complementary information to genetic studies:

• Expression-genotype correlation:

  • Genetic studies identified variants like HTR3B p.Y129S as associated with BPAD

  • Antibodies can determine if variants alter protein expression or localization

  • "The p.129Y allele was overrepresented in patients, and this finding is consistent with previous association data for BPAD, anorexia nervosa and major depression"

• Mechanistic insights:

  • Genetic studies reveal statistical associations

  • Antibodies help determine how variants affect protein function

  • "On a functional level, homozygous 5-HT3AB p.129Y receptors displayed a decreased 5-HT maximum response, caused by a sevenfold decrease in single channel mean open time"

• Cell-type specific effects:

  • Genetic studies typically use DNA from mixed cell populations

  • Antibodies can reveal cell-type specific expression changes

  • "HTR3A interneurons are abundant in the hippocampus and cortex relative to other forebrain regions"

• Temporal and developmental perspectives:

  • Genetics provides a static blueprint

  • Antibodies can track expression changes throughout development or disease progression

  • This temporal dimension is crucial for understanding disease mechanisms

• Therapeutic target validation:

  • Genetic associations suggest potential targets

  • Antibodies help validate those targets at the protein level

  • "Behavioral tests in primates and rodents revealed anxiolytic effects of 5-HT3 antagonists secondary to blockage of the limbic hyperactivity response"

These complementary approaches strengthen the evidential basis for HTR3D's role in psychiatric disorders and provide multiple angles for therapeutic intervention.

How can HTR3D antibodies be used in conjunction with CRISPR technologies for functional studies?

Combining HTR3D antibodies with CRISPR technologies enables powerful functional analyses:

• Knockout verification:

  • CRISPR/Cas9 KO plasmids targeting HTR3D are commercially available

  • Antibodies provide rapid verification of knockout efficiency

  • Western blot and immunofluorescence can confirm protein depletion

• Knock-in studies:

  • HDR plasmids for HTR3D modification are available

  • Antibodies verify successful integration and expression

  • Compare wild-type vs. modified HTR3D expression patterns

• CRISPR activation approaches:

  • CRISPR activation plasmids and lentiviral particles for HTR3D are available

  • Antibodies confirm upregulation of target protein

  • Quantify expression levels in overexpression systems

• Tagged variant studies:

  • Generate epitope-tagged HTR3D using CRISPR

  • Use both anti-tag and anti-HTR3D antibodies to verify expression

  • Track subcellular localization of wild-type vs. variant forms

• Functional rescue experiments:

  • Knockout endogenous HTR3D using CRISPR

  • Reintroduce wild-type or mutant variants

  • Use antibodies to confirm expression of rescue constructs

This combined approach allows researchers to precisely manipulate HTR3D expression while using antibodies to verify modification outcomes and study functional consequences .

What considerations are important when using HTR3D antibodies in Alzheimer's disease research?

Recent research has implicated serotonin receptors in Alzheimer's disease pathology:

• Co-localization studies:

  • Use HTR3D antibodies alongside Aβ markers (e.g., 6E10 antibody)

  • Investigate spatial relationships between HTR3D-expressing neurons and Aβ plaques

  • "HTR3A interneurons are abundant in the hippocampus and cortex... where Aβ plaques are initially present in the early stage of AD"

• Expression changes in disease:

  • Compare HTR3D levels in control vs. AD tissue samples

  • Assess receptor distribution changes in affected brain regions

  • "Inhibiting HTR3 alleviates pathological changes" in AD models

• Functional interactions:

  • "HTR3A interneurons partly contribute to generation of Aβ peptide at the initial stage of Alzheimer's disease"

  • Use antibodies to track expression changes in response to Aβ accumulation

  • Study potential therapeutic effects of HTR3 modulation

• Technical considerations:

  • For co-labeling with Aβ, use rabbit anti-HTR3D with mouse anti-Aβ (6E10) antibodies

  • Consider dual immunohistochemistry protocols optimized for both markers

  • Include P-Tau staining (1:1000, Abcam, Cat# ab32057) for comprehensive AD pathology

• Therapeutic target validation:

  • "Inhibiting HTR3 alleviates pathological changes"

  • Antibodies can confirm target engagement of HTR3-modulating compounds

  • Monitor receptor expression changes following therapeutic intervention

These approaches may reveal new insights into the role of serotonergic signaling in AD pathogenesis and potential therapeutic strategies.

How can epitope-specific antibodies against HTR3D advance receptor-targeted therapeutic development?

Epitope-specific antibodies enable precise targeting for therapeutic development:

• Epitope mapping approaches:

  • Commercial antibodies target different epitopes (e.g., amino acids 10-90, 378-396)

  • Different epitopes may have distinct functional consequences when targeted

  • "Hummingbird Bioscience's epitope-focused discovery approach yields antibodies that bind specific sites on targets to elicit desired functional outcomes"

• Structure-function relationships:

  • Target antibodies to functionally important domains

  • "The RAD platform was used to obtain antibodies that bind a species-conserved epitope in the heterodimerization interface"

  • Study receptor conformational changes upon antibody binding

• Advanced antibody engineering:

  • Create bispecific antibodies targeting HTR3D and potential therapeutic targets

  • "Bispecific antibodies (bsAbs) represent a highly promising class of therapeutic modalities"

  • Combine HTR3D-targeting with other relevant epitopes

• Challenges in antibody design:

  • "The use of two different HC and LC allows flexible pairing of VH and VL domains"

  • "Balanced co-expression of all 4 polypeptide chains can be challenging"

  • Consider single-chain formats to avoid chain mispairing issues

• Machine learning approaches:

  • "Machine learning models can predict target binding by analyzing many-to-many relationships between antibodies and antigens"

  • "Active learning can reduce costs by starting with a small labeled subset of data"

  • Apply computational approaches to optimize epitope-specific antibody development

By focusing on functionally relevant epitopes, researchers can develop more targeted and effective therapeutic antibodies against HTR3D or use such antibodies as tools for validating small-molecule approaches to receptor modulation .

What are common technical challenges when working with HTR3D antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with HTR3D antibodies:

• Low signal intensity:

  • Increase antibody concentration (within recommended range)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification systems (TSA, enhanced chemiluminescence)

  • "Suggested antigen retrieval with TE buffer pH 9.0" for IHC

• High background:

  • Increase blocking time and concentration (5-10% serum/BSA)

  • Use detergent in washing steps (0.1-0.3% Triton X-100 or Tween-20)

  • Reduce secondary antibody concentration

  • Include longer/more wash steps after antibody incubations

• Non-specific bands in Western blot:

  • Optimize protein extraction for membrane proteins

  • Use gradient gels for better resolution

  • Test different blocking agents (BSA vs. milk)

  • Consider membrane stripping and reprobing with different HTR3D antibody

• Inconsistent results between experiments:

  • Standardize tissue/cell preparation protocols

  • Use positive controls in each experiment

  • Prepare antibody aliquots to avoid freeze-thaw cycles

  • "Store at -20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles"

• Antibody cross-reactivity:

  • Validate specificity using CRISPR knockout controls

  • Perform peptide competition assays

  • Test antibody in tissues with known expression patterns

  • Compare results from multiple antibodies targeting different epitopes

Successful HTR3D detection often requires optimization of standard protocols to account for the membrane-bound nature and potentially low expression levels of this receptor .

How can researchers resolve discrepancies between antibody-based and transcript-based HTR3D expression data?

When facing discrepancies between protein and mRNA data:

• Biological explanations:

  • Post-transcriptional regulation may affect protein levels

  • HTR3D protein stability may vary between tissues

  • "Expression of the B subunit was most prominent in the brain stem, amygdalae and frontal cortex" whereas transcript distribution may differ

  • Heteromeric complex formation affects protein stability and detection

• Technical considerations:

  • Antibody may detect specific isoforms or post-translational modifications

  • "HTR3D was detected in all investigated brain tissues with the exception of the cerebellum"

  • Verify antibody specificity with recombinant protein standards

  • Check for epitope masking in certain tissue contexts

• Methodological approaches:

  • Perform parallel quantitative RT-PCR and Western blot on the same samples

  • Use RNAscope to visualize transcripts alongside IF for protein

  • Employ absolute quantification methods for both approaches

  • Test multiple primer sets and antibodies targeting different regions

• Experimental validation:

  • Overexpress HTR3D and measure both transcript and protein levels

  • Use siRNA/shRNA knockdown to confirm specific detection

  • Employ translation inhibitors to study protein turnover rates

  • Investigate regulation of transcript vs. protein across conditions

• Reporting considerations:

  • Clearly document methodology for both transcript and protein detection

  • Specify primer and antibody target regions

  • Note potential confounding factors in interpretation

  • Consider the biological relevance of observed discrepancies

These approaches can help reconcile apparent contradictions and may reveal important insights into HTR3D regulation .

What controls are essential when using HTR3D antibodies for quantitative protein analysis?

For reliable quantitative analysis of HTR3D, include these essential controls:

• Positive controls:

  • Recombinant HTR3D protein at known concentrations

  • HTR3D-overexpressing cell lines

  • Tissues with validated HTR3D expression (brain, particularly hippocampus)

  • "Mouse lung tissue, human brain tissue" for Western blot applications

• Negative controls:

  • Isotype control antibody (same host species and isotype)

  • Tissues known to lack HTR3D expression (e.g., cerebellum)

  • CRISPR knockout models of HTR3D

  • Peptide competition controls

• Normalization standards:

  • Housekeeping proteins for Western blot (β-actin, GAPDH)

  • Total protein staining for normalization (Ponceau S, REVERT)

  • Reference standard curve using recombinant protein

  • Spike-in controls for recovery efficiency

• Technical replicates:

  • Multiple samples processed in parallel

  • Repeated measurements of the same samples

  • Biological replicates from different subjects/sources

  • Multi-site validation for critical findings

• Method validation:

  • Compare results from different antibodies targeting HTR3D

  • Cross-validate with orthogonal methods (mass spectrometry)

  • Test linearity range for quantification

  • Determine lower limit of detection for your specific system

These controls ensure that quantitative measurements of HTR3D are specific, reproducible, and accurately reflect biological reality rather than technical artifacts .